Research programme: potassium channel antagonists - Predix Pharmaceuticals

Drug Profile

Research programme: potassium channel antagonists - Predix Pharmaceuticals

Latest Information Update: 28 Mar 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator EPIX Pharmaceuticals
  • Class
  • Mechanism of Action Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Atrial fibrillation; Brugada syndrome

Most Recent Events

  • 17 Aug 2006 Predix Pharmaceuticals has been acquired and merged into EPIX Pharmaceuticals
  • 04 Apr 2006 No development reported - Preclinical for Brugada syndrome in USA (unspecified route)
  • 27 Mar 2006 Preclinical trials in Atrial fibrillation in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top